期刊文献+

乳腺癌HER2检测指南 被引量:165

原文传递
导出
摘要 一、前言 研究表明,一种受体型的酪氨酸激酶一人类表皮生长因子受体2(HER2)在20%~30%的原发性乳腺浸润性导管癌中有基因的扩增和蛋白的过度表达。HER2阳性的乳腺癌浸润性强,无病生存期短,预后差。《2005 St Gallen国际治疗指南》指出,在乳腺癌风险级别评估因子当中,虽然淋巴结状态仍然是最重要的因素,但HER2状态直接影响风险的级别。当淋巴结阴性或只有1~3个淋巴结有转移时,如HER2过表达或基因扩增则风险级别分别由低上升为中,中上升为高。另外,把HER2状态作为乳腺癌药物(环磷酰胺、阿霉素、5-氟尿嘧啶和曲妥珠单抗)治疗的主要参考指标。
出处 《中华病理学杂志》 CAS CSCD 北大核心 2006年第10期631-633,共3页 Chinese Journal of Pathology
  • 相关文献

参考文献10

  • 1Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583.
  • 2The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html.
  • 3Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77.
  • 4Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047.
  • 5北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm.
  • 6Hicks DG,Tubbs RR.Assessment of the Her2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines.Hum Pathol,2005,36:250-261.
  • 7Wang S,Hossein Saboorian H,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol,2002,15:137-145.
  • 8Risio M,Casorzo L,Redana S,et al.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.Oncol Rep,2005,13:305-309.
  • 9Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114.
  • 10Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124.

同被引文献1608

引证文献165

二级引证文献1675

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部